Clinical Trial Update: A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16 [Phase 2]

View source ↗

Summary

Phase 2 study completed examining the duration of effect of PrEP-001 in healthy subjects challenged with HRV-16 for viral upper respiratory tract infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Viral Upper Respiratory Tract Infection

Drugs mentioned

• PrEP-001

Snippet

Sponsor: Prep Biopharm Limited | Conditions: Viral Upper Respiratory Tract Infection | Phase 2 | Status: COMPLETED | Results posted: 2018-06-27